Researchers sought to determine whether combination therapies with carfilzomib would be feasible for patients with relapsed/refractory multiple myeloma.
Researchers sought to assess the disease-specific costs for Medicare recipients with multiple myeloma.
The overall response rate was 100%.
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.
A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.
The 5-year survival rate was longer with CPX-351 than with conventional chemotherapy.
Researchers sought to determine the real-world renal function and outcomes for patients with multiple myeloma according to type of treatment and line of therapy.
Progression-free and overall survival outcomes were similar with and without ofatumumab.
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Researchers sought to determine whether poorer health-related quality of life would be linked to responses about pain severity in patients with multiple myeloma.
During a residential rehabilitation program, researchers interviewed participants to determine their supportive care and rehabilitation needs.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Influencing factors include hospital size, insurance type, geographic region.
The approval was based on data from the phase 3 APOLLO trial.
Considerable variation seen in magnitude of antibody response, from 5 to 7,882 AU/mL, following two doses of mRNA COVID-19 vaccine.
Quality of life outcomes were generally the same from baseline through follow-up.
A chemoimmunotherapy regimen with only 3 cycles of chemotherapy was found to be efficacious in a phase 2 trial that sought to reduce treatment-related MDS/AML in patients with CLL.
The results point to patients who might benefit from early intervention.
Adding isatuximab to carfilzomib and dexamethasone improved outcomes.